Of 123 vaccines, seven enter human trials

Published May 16, 2020
Health officials argue that the large number of vaccine candidates shows that the entire world is focusing on a cure. — AFP/File
Health officials argue that the large number of vaccine candidates shows that the entire world is focusing on a cure. — AFP/File

WASHINGTON: An American biotech company Sorrento Therapeutics (SRNE) reported on Friday that it has a cure for the coronavirus disease.

The same day, the CBS news channel reported that the US National Institutes of Health (NIH) has confirmed reports that researchers have begun testing a potential coronavirus vaccine.

Yet another biotech also said it has gained approval for a new method of coronavirus tests.

SRNE Chief Executive Henry Ji told Fox News the antibody drug his company has produced can provide “100 per cent inhibition” of Covid-19. “We want to emphasise there is a cure,” he said. “If we have the neutralising antibody in your body, you don’t need the social distancing.” The claim caused a 51.5 percent increase in Sorrento’s shares in the stock market.

But the Milken Institute, a US think tank that monitors such research works, urged caution. “Some 200 therapeutics are being developed as possible treatments for Covid-19; and a remarkable 123 vaccines are under development to prevent infections,” it pointed out. Of these, only seven have entered human trials.

Health officials argue that the large number of vaccine candidates shows that the entire global community was focused on finding a cure to a disease that has killed more than 300,00 people and infected close to 4.5 million. But they also acknowledge that so many claims and counter-claims cause confusion and despair as none of these experiments have yet led to a definite cure.

In a report for the World Economic Forum, the Chief Executive Officer of a US pharmaceutical giant, Modern, urged people “not to take false hope from the number of vaccine candidates,” as 123 were far too many.

CEO Stéphane Bancel, however, also noted that the acceptance of seven of these vaccines for human trials was very a positive sign. “This progress in a record timeframe is indeed encouraging – and a legitimate, medical reason for hope,” he wrote.

Moderna’s vaccine was the first to enter human clinical trials in the United States, back on March 16. Six other vaccines come from the Beijing Institute of Biological Products, BioNTech (BNT162), CanSino Biologics (Ad5-nCoV), Inovio

Pharmaceuticals (INO-4800), Sinovac Biotech, and University of Oxford (ChAdOx1 nCoV-19).

The Wall Street Journal reported this week that a dozen of America’s top scientists, financers and industry titans have formed a group — called “Scientists to Stop Covid-19” — to find a cure or a prevention for this disease.

They have pledged not to make profit from this project and to sell whatever shares they might have in the companies that could benefit from their recommendations. One member who did not was asked to leave.

Published in Dawn, May 16th, 2020

Opinion

Editorial

Smog hazard
Updated 05 Nov, 2024

Smog hazard

The catastrophe unfolding in Lahore is a product of authorities’ repeated failure to recognise environmental impact of rapid urbanisation.
Monetary policy
05 Nov, 2024

Monetary policy

IN an aggressive move, the State Bank on Monday reduced its key policy rate by a hefty 250bps to 15pc. This is the...
Cultural power
05 Nov, 2024

Cultural power

AS vital modes of communication, art and culture have the power to overcome social and international barriers....
Disregarding CCI
Updated 04 Nov, 2024

Disregarding CCI

The failure to regularly convene CCI meetings means that the process of democratic decision-making is falling apart.
Defeating TB
04 Nov, 2024

Defeating TB

CONSIDERING the fact that Pakistan has the fifth highest burden of tuberculosis in the world as per the World Health...
Ceasefire charade
Updated 04 Nov, 2024

Ceasefire charade

The US talks of peace, while simultaneously arming and funding their Israeli allies, are doomed to fail, and are little more than a charade.